Federal Government Lends Struggling Kodak $765 Million to Produce Drug Ingredients
The Trump administration provides a massive loan to Eastman Kodak to manufacture pharmaceutical ingredients, aiming to reduce US reliance on foreign supply chains. Lawmakers question whether this new domestic focus distracts from the agency's original international mission.
The Trump administration announces a $765 million loan to Eastman Kodak so the struggling camera company can start manufacturing active pharmaceutical ingredients. This funding marks the first investment from the U.S. International Development Finance Corp. under a new executive order that allows the agency to use Defense Production Act funds for domestic supply chains.
Kodak plans to retool its existing chemical plants in Rochester, N.Y., and St. Paul, Minn., to produce ingredients for generic drugs. Administration officials state that this initiative eventually supplies 25% of the active pharmaceutical ingredients needed in the United States, specifically addressing the heavy reliance on Chinese factories exposed by the pandemic.
Lawmakers on the House Appropriations Committee ask the Government Accountability Office to review this unusual loan. They question whether directing foreign investment funds toward a domestic camera company distracts from the agency's core mission of countering China's global infrastructure projects abroad.